Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Aldolase. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN106795542B details (R)-selective cupin enzymes for chiral beta-nitroalcohol synthesis, offering high purity and cost reduction in API manufacturing.
Patent CN116286761A reveals novel aldolase screening for 4-hydroxy-2-ketobutyric acid synthesis. Enables cost-effective, scalable biomanufacturing of key pharmaceutical intermediates.
Patent CN114703169A reveals a novel L-threonine aldolase mutant for Droxidopa. Achieves 92.89% selectivity. Ideal for pharma intermediates supply.
Patent CN110869383A reveals enzymatic synthesis of beta-hydroxy-alpha-amino acids with high stereoselectivity and reduced environmental impact for supply chains.
Novel enzymatic route for (2S,3R)-p-methylsulfonylphenylserine ethyl ester eliminates copper waste and resolution steps, offering cost-effective API intermediate supply.
Patent CN115109769B reveals L-threonine aldolase mutants enabling >99% conversion for L-serine synthesis. Discover cost-effective biocatalytic solutions for pharmaceutical intermediates.
Patent CN112011580B reveals a novel aldolase-catalyzed route for Droxidopa. Achieve high stereoselectivity and cost reduction in pharmaceutical intermediates manufacturing.
Patent CN113337494B reveals high-purity enzymatic synthesis reducing waste and cost for reliable pharmaceutical intermediates supply chains globally.
Novel L-threonine aldolase enables green synthesis of antibiotic intermediates with high stereoselectivity and reduced environmental impact.
Novel enzymatic method using L-threonine improves yield and stereoselectivity for Droxidopa production, offering significant cost and supply chain advantages.
Patent CN115109769A reveals T202S/T202G mutants enabling >99% conversion at high formaldehyde concentrations for efficient L-serine production.